We work with families and patient organisations to ensure our programmes deliver the best treatments for patients.
NovalGen is focused on bispecific antibody treatments and has developed a bispecific antibody T cell engager treatment that provides a potentially efficacious yet more straightforward and less invasive treatment approach than CAR-T cells which require ex vivo manipulation and T cell engineering
NovalGen is committed to developing innovative treatments. We operate with integrity and carefully test our new treatments in well-designed clinical trials to ensure safety and efficacy.
